Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | ERN1 | O75460 | 5/20 | 0.40 |
| ▸ | MARS1 | P56192 | 1/20 | 0.40 |
| ▸ | AHR | P35869 | 1/20 | 0.38 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.37 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.36 |
| ▸ | TTR | P02766 | 1/20 | 0.35 |
| ▸ | XDH | P47989 | 1/20 | 0.35 |
| ▸ | KMO | O15229 | 2/20 | 0.35 |
| ▸ | ACLY | P53396 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4598990 | 0.88 | ERN1 (0.40) | ERN1ALDH1A1MAPTEPAS1KMO | |
| SCHEMBL4600254 | 0.88 | ERN1 (0.40) | TDP1ERN1ANO1EPAS1XDH | |
| SCHEMBL5622410 | 0.84 | ERN1 (0.48) | TDP1ERN1ANO1ALDH1A1MAPT | |
| SCHEMBL32682731 | 0.84 | ERN1 (0.47) | TDP1ERN1ANO1ALDH1A1EPAS1 | |
| SCHEMBL20303480 | 0.84 | ERN1 (0.47) | TDP1ERN1ANO1ALDH1A1EPAS1 | |
| SCHEMBL4600016 | 0.84 | AR (0.34) | ERN1KMO | |
| SCHEMBL867818 | 0.82 | TDP1 (0.39) | TDP1ERN1MARS1AHRALDH1A1 | |
| SCHEMBL14609760 | 0.81 | GRIN2B (0.38) | ERN1KMONOTUM | |
| SCHEMBL14499539 | 0.79 | FFAR1 (0.44) | MARS1AHRANO1SRD5A2RORC | |
| SCHEMBL5620852 | 0.77 | PIM1 (0.43) | ERN1ALDH1A1MAPTEPAS1TTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070149570-A1 | Piperidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-06-28 | — | — | US | disclosed |
| US-20070149570-A1 | Piperidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-06-28 | — | — | US | disclosed |
| US-20070149570-A1 | Piperidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149570-A1 | Piperidine derivative and use thereof | TACR1, OPRL1, TRPV1 | TDP1 4854/4885ERN1 4124/4885MARS1 4218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.